Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: tirsdag 17. oktober
Teknisk analyse
Nyheter
Om BGBIO
Meglerandel
Intradagsgraf
Korrelasjoner
Handelslogg
Dybdelogg
Dataeksport
Legg til interesseliste
Handle BGBIO
Sanntidssnapshot
Dato Antall dager Distributør Papir Børs Søk  
Dato Tid Selskap Overskrift
16/10-2017 08:00:12 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (OBI)
  08:00:11 BGBIO Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (OBI)
  08:00:00 BGBIO Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (Cision)
  08:00:00 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (Cision)
12/10-2017 08:23:00 BGBIO BerGenBio skal holde presentasjon i Australia (Hegnar)
  08:00:16 BGBIO Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma (OBI)
  08:00:16 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma (OBI)
  08:00:00 BGBIO Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma (Cision)
  08:00:00 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma (Cision)
28/09-2017 08:53:00 BGBIO BergenBio oppdaterer markedet (Hegnar)
  08:00:14 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer (OBI)
  08:00:00 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer (Cision)
18/08-2017 08:21:00 BGBIO Mindre minus for BerGenBio (Hegnar)
  07:00:10 BGBIO BerGenBio ASA: Results for the Second Quarter and Half year 2017 (OBI)
  07:00:00 BGBIO BerGenBio ASA: Results for the Second Quarter and Half year 2017 (Cision)
11/08-2017 08:05:15 BGBIO BerGenBio ASA: Invitation to Second Quarter and Half year 2017 Results Presentation and Webcast (OBI)
26/07-2017 08:00:06 BGBIO BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston (OBI)
  08:00:00 BGBIO BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston (Cision)
13/07-2017 13:12:42 BGBIO BerGenBio ASA: Share capital increase registered (OBI)
27/06-2017 08:00:23 BGBIO BerGenBio ASA: Exercise of employee share options and increase of share capital (OBI)
26/06-2017 09:02:00 BGBIO AKSO STL Oslo Børs åpner opp (Hegnar)
  08:17:00 BGBIO BergenBio tildelt 24 millioner kroner (Hegnar)
  08:00:11 BGBIO BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer (OBI)
  08:00:00 BGBIO BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer (Cision)
06/06-2017 08:00:12 BGBIO BerGenBio's selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 (OBI)
  08:00:00 BGBIO BerGenBio's selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 (Cision)
30/05-2017 14:50:00 BGBIO Ser saftig oppside i BerGenBio (Hegnar)
23/05-2017 07:33:00 BGBIO Underskuddet vokser for BerGenBio (Hegnar)
  07:00:25 BGBIO BerGenBio ASA: Results for the First Quarter 2017 (OBI)
22/05-2017 08:43:00 BGBIO BerGenBio starter undersøkelser (Hegnar)
  08:00:15 BGBIO BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma (OBI)
  08:00:00 BGBIO BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma (Cision)
19/05-2017 08:39:00 BGBIO BerGenBio oppdaterer markedet (Hegnar)
  08:00:27 BGBIO Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 (OBI)
  08:00:00 BGBIO Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 (Cision)
16/05-2017 08:00:17 BGBIO BerGenBio ASA: First Quarter 2017 Results Presentation and Webcast (OBI)
08/05-2017 08:36:28 BGBIO BerGenBio ASA - Stabilisation notice (OBI)
06/04-2017 08:27:00 BGBIO BerGenBio i mål - på børs fredag (Hegnar)
Sidestørrelse:
Utforming |  Hjelp |  Utskrift  | Bytt til sanntid Ingen åpne markeder
tirsdag 17/10-2017 07:54:08